^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    LMB-2

    i
    Other names: LMB-2, Anti-Tac(Fv)-PE38, Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin
    Associations

    News

    Trials
    Company:
    National Cancer Institute
    Drug class:
    IL-2R antagonist
    Related drugs:
    Associations

    News

    Trials
    6ms
    LMB-2 to Treat Hairy Cell Leukemia (clinicaltrials.gov)
    P2, N=15, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: Mar 2024 --> Dec 2022
    Trial completion • Trial completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    IL2RA positive
    |
    LMB-2
    6ms
    Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia (clinicaltrials.gov)
    P1/2, N=18, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Phase classification: P2 --> P1/2
    Trial completion • Phase classification
    |
    cyclophosphamide • Campath (alemtuzumab) • fludarabine IV • LMB-2
    2years
    LMB-2 to Treat Hairy Cell Leukemia (clinicaltrials.gov)
    P2, N=15, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2022 --> Mar 2024
    Trial completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    IL2RA positive
    |
    LMB-2
    3years
    LMB-2 to Treat Hairy Cell Leukemia (clinicaltrials.gov)
    P2, N=15, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2021 --> Mar 2022
    Clinical • Trial completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    IL2RA positive
    |
    LMB-2